Funding

This study was funded by AbbVie, Inc. (North Chicago, IL, USA). AbbVie participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of this publication. No honoraria or payments were made for authorship.

Conflict of interest

KAP has received honoraria and/or grants from AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Janssen, Kymab, Kyowa Hakko Kirin, LEO, Lilly, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB, and Zai Lab. MGL is an employee of Mount Sinai and received research funds from AbbVie, Aikium, Almirall, AltruBio, Amgen, Apogee, Arcutis, AstraZeneca, Atomwise, Avotres, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celltrion, Clexio, CorEvitas, Dermavant, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, Inozyme, LEO, Lilly, Johnson & Johnson, Mayne, Meiji Seika, Mindera, Mirium, Oruka, Pfizer, Revolo, Sanofi-Regeneron, Seanergy, Strata, Sun Pharma, Takeda, Trevi, UCB, and Verrica. He also serves as an Editorial Board member of the American Journal of Clinical Dermatology and was not involved in the selection of peer reviewers for the manuscript, nor any of the subsequent editorial decisions. LP has received consultancy fees, speaker’s fees, or fees for participating in clinical trials sponsored by AbbVie, Almirall, Amgen, Baxalta, Boehringer Ingelheim, Biogen, Celgene, EMD Serono, Gebro, Janssen, LEO, Lilly, Merck, Mylan, Novartis, Pfizer, Regeneron, Roche, Samsung Bioepis, Sandoz, Sanofi, and UCB. MO has received honoraria for participating on advisory boards, serving on speakers’ bureaus and consulting, as well as grants for investigator activities from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Janssen, Kyowa Kirin, LEO, Lilly, Maruho, Mitsubishi Tanabe, Novartis, Pfizer, Sun, Taiho, Torii, and UCB. SB has received honoraria as an advisory board member and/or speaker for AbbVie, Actelion, Almirall, Amgen, Bristol Myers Squibb, Celgene, Galderma, GSK, Janssen, LEO, Lilly, Menlo, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB. MG is or has been an investigator, adviser, and/or speaker for AbbVie, Akros, Amgen, AnaptysBio, Arcutis, Aristea, Bausch, Boehringer Ingelheim, Bristol Myers Squibb, Coherus BioSciences, Dermavant, Dermira, Galderma, GlaxoSmithKline, JAMP, Janssen, Kyowa Kirin, LEO, Lilly, Medimmune, Meiji, Merck, Moonlake, Nimbus, Novartis, Oruka, Pfizer, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, UCB, Ventyx, and Vyne. AZA is a consultant and speaker for AbbVie, Amgen, Janssen, Lilly, Pfizer, Sanofi Genzyme, and UCB. TW, SR, BB, DA, AMS, and MMC are full-time employees of AbbVie Inc., and may hold AbbVie stock, stock options, and/or patents. AB has served as a speaker (received honoraria) for Almirall, Lilly, and UCB. He has served as a scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Corvus, Dermavant, Galderma, GlaxoSmithKline, Immunovant, Incyte, IQVIA, Janssen, LEO, Lilly, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Syncona, Takeda, UCB, Union, and Zai Lab. He also has served as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Janssen, LEO, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB. He owns stock in Lipidio and Oruka.

Data availability

AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal, statistical analysis plan (SAP), and execution of a data sharing agreement (DSA). Data requests can be submitted at any time after approval in the United States and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link: https://vivli.org/ourmember/abbvie/ then select “Home.”

Ethics approval and consent to participate

All patients provided written informed consent before study initiation. The study protocol adhered to the Declaration of Helsinki, International Conference for Harmonisation guidelines, and other relevant regulations. The study was approved by central (Advarra IRB Services, Columbia, MD, USA) and local, independent ethics committees and/or institutional review boards at each participating study site.

Consent to publish

Not applicable.

Code availability

Not applicable.

Author contributions

KAP, MGL, LP, MO, SB, SR, and AB contributed to the conception and design of the work. KAP, MGL, LP, MO, SB, SR, AB, and TW contributed to data acquisition. TW, SR, BB, DA, AMS, and MMC contributed to the analysis of the data. All authors contributed to interpretation of the data. All authors had access to relevant data and participated in the drafting, review, and approval of this publication.